ECR 2008 / C-253
Radiofrequency ablation and cryotherapy for inoperable pulmonary lung malignancy
Authors:
G.-Y. Jin, Y. C. Lee, Y. H. Choi, Y. M. Han; Jeon-ju/KP
DOI:
10.1594/ecr2008/C-253
Purpose
- Until recently, non-invasive therapy such as chemotherapy, radiation therapy, or both may be considered for cure or expectant palliative treatment and even in cases of regional disease, a combination therapeutic strategy prevails as the standard treatment. Although these modalities produce a modest improvement in survival, some patients suffer from substantial toxicity, especially in patients who already have other co-morbidities.[1-2]
- Previous studies have shown that radiofrequency ablation (RFA) as an alternative management for lung malignancies has advantages over traditional radiation therapy and systemic chemotherapy.Very recently, some studies have demonstrated that percutaneous thoracic cryotherapy (PTC) is associated with low procedural morbidity and also appears to treat lung mass.[3-12]
- We evaluated the therapeutic efficacies, survival duration, and complication in patients with primary lung malignancy treated with radiofrequency ablation or cryotherapy.